Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Sutro Biopharma revenue
Sutro Biopharma's revenue is $62.0 million.
What is Sutro Biopharma's revenue?
- Sutro Biopharma's revenue growth from 2017 to 2024 is 19.91%.
- Sutro Biopharma has 160 employees, and the revenue per employee ratio is $387,768.
- Sutro Biopharma's peak quarterly revenue was $113.7M in 2023(q4).
- Sutro Biopharma peak revenue was $153.7M in 2023.
- Sutro Biopharma annual revenue for 2023 was 153.7M, 126.84% growth from 2022.
- Sutro Biopharma annual revenue for 2024 was 62.0M, -59.64% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Sutro Biopharma historical revenue
Sutro Biopharma's peak revenue was $153.7M in 2023. The peak quarterly revenue was $113.7M in 2023(q4).
Sutro Biopharma's revenue increased from $51.7m in 2017 to $62.0M currently. That's a 19.91% change in annual revenue.
Sutro Biopharma annual revenue
Sutro Biopharma annual revenue over time
| Fiscal year / year | Sutro Biopharma revenue |
|---|---|
| 2017 | $51.7M |
| 2018 | $38.4M |
| 2020 | $42.7M |
| 2021 | $61.9M |
| 2022 | $67.8M |
| 2023 | $153.7M |
| 2024 | $62.0M |
How accurately did Sutro Biopharma's revenue projections match actual performance?
Sutro Biopharma annual growth
Sutro Biopharma saw the greatest revenue growth in 2021, when revenue increased by 44.84%.
Sutro Biopharma had the lowest revenue growth in 2018, when revenue changed by -25.75%.
Sutro Biopharma annual growth rate over time
| Year | Sutro Biopharma growth |
|---|---|
| 2018 | -26%↓ |
| 2020 | 11%↑ |
| 2021 | 45%↑ |
| 2022 | 10%↑ |
| 2023 | 127%↑ |
| 2024 | -60%↓ |
Sutro Biopharma quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Sutro Biopharma quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | $7.8M | $19.1M |
| 2020 | $7.2M | $9.5M | $17.8M | $8.3M |
| 2021 | $14.7M | $28.0M | $8.5M | $10.7M |
| 2022 | $5.9M | $28.1M | $25.1M | $8.6M |
| 2023 | $12.7M | $10.4M | $16.9M | $113.7M |
| 2024 | $13.0M | $25.7M | $8.5M | $14.8M |
Sutro Biopharma jobs nearby
Do you work at Sutro Biopharma?
Is Sutro Biopharma transparent about its revenue structure?
Sutro Biopharma financial information
| CEO | William J. Newell |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 160 |
| Date Founded | 2003 |
| Headquarters | South San Francisco, California |
| Revenue | $62.0M |
| Net Income | -$119,204,000 |
| Tax Rate | -0.0% |
| Total Assets | $406,944,000 |
| Ticker | STRO |
Sutro Biopharma jobs you might like
Sutro Biopharma financing
Sutro Biopharma received early financing of $1.0M on 2006-01-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $1M | 01/2006 |
| Series Unknown | $305K | 10/2007 |
| Series B | $21M | 12/2007 |
| Series B | $15M | 03/2009 |
| Series C | $36.5M | 11/2010 |
| Series C | $16.5M | 05/2012 |
| Series D | $26M | 12/2013 |
| Series E | $85.4M | 07/2018 |
| Post Ipo Equity | $144.9M | 12/2020 |
Sutro Biopharma investors
| Investors | Security type |
|---|---|
| SV Health Investors LLC | Series A |
| International Biotechnology Trust | Series Unknown |
| SV Health Investors LLC | Series Unknown |
| Alta Partners | Series B |
| SV Health Investors LLC | Series B |
| Alta Partners | Series B |
| SV Health Investors LLC | Series B |
| Skyline Ventures | Series C |
| Lilly Ventures | Series C |
| Alta Partners | Series C |
| SV Health Investors LLC | Series C |
| Amgen | Series C |
| Skyline Ventures | Series C |
| Lilly Ventures | Series C |
| Alta Partners | Series C |
| SV Health Investors LLC | Series C |
| Amgen | Series C |
| Celgene Corporation | Series D |
| Skyline Ventures | Series D |
| Eli Lilly | Series D |
| Alta Partners | Series D |
| SV Health Investors LLC | Series D |
| Amgen | Series D |
| Celgene Corporation | Series E |
| Nexthera Capital LP | Series E |
| Tekla Capital Management | Series E |
| Vida Ventures LLC | Series E |
| Lilly Ventures | Series E |
| MERCK & CO., INC. | Series E |
| Alta Partners | Series E |
| SV Health Investors LLC | Series E |
| Amgen | Series E |
| Centene Corporation | Series E |
| Samsara BioCapital | Series E |
| Surveyor Capital | Series E |
| Eventide | Series E |
| Citadel | Series E |
| Skyline Ventures | Series E |
Sutro Biopharma competitors
Sutro Biopharma's top competitor, Merck, earned an annual revenue of $64.2B.
Sutro Biopharma's smallest competitor is Cynvenio Biosystems with revenue of $1.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 343 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 733 |
| Merck | $90,328 | $64.2B | 74,000 | 1,711 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Exelixis | $108,978 | $2.2B | 484 | 162 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Zoetis | $87,092 | $9.3B | 11,300 | 236 |
| Amneal Pharmaceuticals | $76,227 | $2.8B | 6,500 | 106 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 130 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Sutro Biopharma highest paying jobs
Zippia gives an in-depth look into the details of Sutro Biopharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Sutro Biopharma. The employee data is based on information from people who have self-reported their past or current employments at Sutro Biopharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Sutro Biopharma. The data presented on this page does not represent the view of Sutro Biopharma and its employees or that of Zippia.
Sutro Biopharma may also be known as or be related to SUTRO BIOPHARMA INC, SUTRO BIOPHARMA, INC., Sutro Biopharma, Sutro Biopharma Inc. and Sutro Biopharma, Inc.